Loading... Please wait...

Our Newsletter






Nalbin 10mg/1ml by Global Pharma x 1 Amp

  • Image 1
3.00 Grams
Calculated at checkout
Bookmark and Share

Product Description


Generic Name:

Nalbuphine (HCl)

Nalbin is a synthetic opiate agonist/antagonist that is chemically related to both naloxone, a narcotic antagonist, and oxymorphone, a potent narcotic analgesic. Used to treat moderate to severe pain associated with acute and chronic medical disorders such as cancer, renal or biliary colic, migraine or vascular headaches, and surgical pain. Another clinical use is obstetrical analgesia during labor and delivery. Some evidence suggests that nalbuphine's respiratory depressant effects do not increase proportionately with increasing doses, thus making this drug safer in patients at risk from respiratory depression. It was approved by the FDA in 1979. Nalbuphin exerts its effects by binding to specific opiate receptors present in the central nervous system, functions as an antagonist at the µ-receptor, however it has agonist action at ?-receptor, Nalbuphine is also an agonist at the d-receptor, but Nalbuphine (HCl) is nalbuphine's action at the ?-receptor that provides analgesia. Actions at the ?-receptors are believed to produce alterations in the perception of pain as well as the emotional response to pain, possibly by altering the release of neurotransmitters from afferent nerves sensitive to painful stimuli.

Find Similar Products by Category

Write your own product review

Product Reviews

  1. Nelbin is a great pain killer

    Posted by elbert on 9th Nov 2015

    I have used nelbin a couple of times and i found it a very useful pain killer

  2. In every business tr

    Posted by Beatriz on 11th Aug 2015

    In every business trcaiantson the ultimate question is: Who is the customer? When buying a house, this is the wife. (Sorry guys.) This carries with it the issue of: Who is the decision maker? DTC ads may drive demand, but the doctor is the ultimate customer.A recent flurry of articles has appeared about a situation at the M.D. Anderson Cancer Center regarding the increased profits and reduced nonpayment due to a "pay first" policy. A tax supported, nonprofit, part of the University of Texas system, this institution takes advantage of it's status to also garner large donations. What we see here, from my perspective, is the institution becoming the ultimate customer, patients are incidental to the operation.The case in question focuses on the demands of the institution for rather large sums of money, $45,000 for initial test, and then an additional on the spot payment of $60,000 for continued treatment. At one point "a payment representative accompanied the doctor into the exam room...(and) this was an example of a coordinated teamwork approach." (April 28.2008 WSJ Bad Debts Prompt Hospitals to Demand Patients' Cash Upfront)From the April 4, WSJ Nonprofit Hospitals, Once For the Poor, Strike It Rich we learn that the bulk of the hospitals in the US are nonprofit, they have a higher percentage of hospitals in the black (77% v 61%), and a smaller percentage of it's income is spent on charity care than for-profit hospitals. All the while CEO compensation rivals or surpasses that of for-profit companies.The ultimate customer in these situations appears to be the institution, not the patient. Payment first, treatment second, places financial gain as the primary driver in these trcaiantsons. Staff salaries, perks are the goal, not patient treatment. The April 4, WSJ article points out questionable expenses as part of hospital operations having nothing to do directly with the hospital or patient care. Out of market advertising being but one example.Much has been made of alternatives for the patients involved. The patient reality is many nonprofit's have used their position to eliminate competition. They are the only service provider in a given geographic area, thus allowing them monopoly status.Much like the FDA example, the institution itself has become the focus of the operation. We have seen a shift from safety and patient care to a focus on institutional priorities. Dr. Gaulte is correct: "Follow the money."Steve Lucas

Add to Wish List

Click the button below to add the Nalbin 10mg/1ml by Global Pharma x 1 Amp to your wish list.

You Recently Viewed...